ArticleDiscover oncology2026
Construction of a prognostic prediction model for diffuse large B-cell lymphoma patients based on ferroptosis-related LncRNAs.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the prognostic value of a model based on ferroptosis-related long non-coding RNAs (lncRNAs) for patients with diffuse large B-cell lymphoma (DLBCL).
methodsFerroptosis-related lncRNA expression matrices and corresponding clinical information for DLBCL patients were downloaded from the GEO public database (datasets GSE10846 and GSE11318). A prognostic risk model was constructed using the GSE10846 dataset through the following steps: identification of ferroptosis-related genes, Pearson correlation analysis with lncRNAs, Kaplan-Meier survival analysis, univariate Cox regression analysis, LASSO regression analysis, and multivariate Cox regression analysis. The accuracy of the model was evaluated using Receiver Operating Characteristic (ROC) curves. The model was subsequently validated using the GSE11318 dataset. Further systematic assessments of the model's biological significance and clinical translational potential were conducted via immune infiltration analysis and drug sensitivity prediction.
resultsA prognostic model comprising 9 lncRNAs was established. Time-dependent ROC curve analysis showed that the Area Under the Curve (AUC) values for 3-year and 5-year survival predictions were both greater than 0.75. Consistent results were obtained in the validation set, indicating good model robustness. Immune microenvironment analysis revealed that the high-risk group exhibited an immunosuppressive "cold tumor" phenotype, characterized by a significant reduction in the infiltration of effector immune cells such as cytotoxic cells and CD8⁺ T cells (all P < 0.001). Drug sensitivity analysis indicated that the high-risk group was more sensitive to PI3K/mTOR inhibitors (e.g., Dactolisib) but showed resistance to certain histone deacetylase inhibitors. Enrichment analysis suggested that these lncRNAs might influence DLBCL progression by regulating pathways such as protein degradation and RNA processing.
conclusionThe prognostic model constructed based on ferroptosis-related lncRNAs demonstrates considerable reliability. It not only effectively predicts patient survival but also reflects tumor immune status and drug response characteristics, showing potential as an auxiliary tool for prognosis assessment and personalized treatment in DLBCL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.